Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE SR vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It produces relaxation of coronary vascular smooth muscle and dilation of coronary arteries, and also dilates peripheral arteries, reducing systemic vascular resistance and blood pressure.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Hypertension,Chronic stable angina
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Initial: 30 mg orally twice daily (SR capsules). Titrate up to 60 mg twice daily. Usual maintenance: 30-60 mg twice daily.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Terminal elimination half-life 8.6 hours (range 6-15 hours). Clinical context: No accumulation at steady state with TID dosing.
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Primarily hepatic via cytochrome P450 (CYP3A4) isoenzyme.
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Renal: 60% (metabolites, unchanged drug <1%); Biliary/Fecal: 35%
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
95-98%, primarily to albumin and alpha-1-acid glycoprotein
92-98% bound primarily to albumin.
0.3-0.7 L/kg. Clinical meaning: Indicates extensive tissue distribution.
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
Oral: 35% (first-pass metabolism); Food does not significantly affect bioavailability.
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
No specific GFR-based dose adjustment provided by manufacturer; use with caution in renal impairment, especially if concurrent hepatic impairment.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
Child-Pugh Class A: No adjustment. Child-Pugh Class B/C: Consider starting at 15 mg twice daily and titrate slowly due to increased bioavailability.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Not established; safety and efficacy in pediatric patients have not been determined.
Safety and efficacy not established; use is not recommended in pediatric patients.
Start at lower initial dose (15 mg twice daily) and titrate cautiously due to increased bioavailability and slower elimination.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
None.
No FDA black box warning.
Use caution in patients with coronary artery disease; may cause increased angina or acute myocardial infarction upon initiation or dose titration. Also caution in patients with congestive heart failure, hepatic impairment, or renal impairment. Monitor blood pressure during titration.
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Hypersensitivity to nicardipine or any component; advanced aortic stenosis.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Grapefruit and grapefruit juice increase nicardipine serum concentrations by inhibiting CYP3A4 metabolism. Avoid concurrent use. High-fat meals may increase absorption; take consistently with regard to meals. Alcohol may enhance hypotensive effects; limit intake.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
Nifedipine, the active ingredient in Cardene SR, is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, nifedipine has been shown to cause embryotoxicity, placentotoxicity, and fetotoxicity at doses several times the maximum recommended human dose. First trimester: Risk cannot be ruled out; potential for teratogenic effects based on animal data. Second and third trimesters: May cause maternal hypotension and fetal distress due to placental hypoperfusion; use only if benefit outweighs risk. Case reports of fetal distress, perinatal asphyxia, and cesarean delivery associated with use in preterm labor.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Nifedipine is excreted into human breast milk. The milk-to-plasma ratio (M/P) is approximately 1.0. Limited data suggest infant doses are low (less than 5% of maternal weight-adjusted dose). However, due to potential for adverse effects in infants (e.g., hypotension), caution is advised. Use only if clearly needed and monitor infant for bradycardia and hypotension.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
Pregnancy does not necessitate routine dose adjustment of oral nifedipine. However, due to increased plasma volume and clearance in pregnancy, lower doses may be effective for hypertension. For tocolysis (off-label), dosing regimens vary (e.g., 10-20 mg oral immediate-release every 4-6 hours). Monitor for hypotension; dose should be individualized based on blood pressure response.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
CARDENE SR (nicardipine) is a dihydropyridine calcium channel blocker used for hypertension. Avoid in advanced aortic stenosis due to risk of reduced coronary perfusion. Monitor for peripheral edema, especially in elderly. Use caution in heart failure with reduced ejection fraction due to negative inotropic effects (though less than verapamil). May increase cyclosporine levels; monitor levels. For IV use (not SR), titrate rapidly for hypertensive emergency. Do not crush or chew SR capsules.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
Take exactly as prescribed, usually twice daily. Swallow SR capsules whole; do not crush or chew.,Avoid grapefruit and grapefruit juice as they can increase drug levels and side effects.,May cause dizziness or lightheadedness; avoid driving until you know how you react. Rise slowly from sitting or lying.,Notify your doctor if you experience swelling in ankles or feet, rapid heartbeat, or shortness of breath.,Do not stop abruptly; sudden withdrawal may worsen chest pain or blood pressure.,Keep a daily blood pressure log to track effectiveness.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE SR vs ADALAT CC, answered by our medical review team.
CARDENE SR is a Calcium Channel Blocker that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It produces relaxation of coronary vascular smooth muscle and dilation of coronary arteries, and also dilates peripheral arteries, reducing systemic vascular resistance and blood pressure.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE SR and ADALAT CC depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE SR is: Initial: 30 mg orally twice daily (SR capsules). Titrate up to 60 mg twice daily. Usual maintenance: 30-60 mg twice daily.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE SR and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE SR is classified as Category C. Nifedipine, the active ingredient in Cardene SR, is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, . ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.